Biomoneta Research

What Biomoneta Research does

Biomoneta Research Private Limited is a Bangalore-based health technology company founded in 2014 that develops air decontamination hardware for healthcare and consumer settings. The company's proprietary ZeBox platform uses non-ionizing electric fields combined with microbicidal agent-coated 3D-textured electrodes to capture and destroy airborne microorganisms at >99.999% efficiency, validated against pathogens including SARS-CoV-2, Mycobacterium tuberculosis, H1N1, MRSA, and VRE in peer-reviewed studies and ICMR/NABL-accredited laboratories. The product portfolio comprises two hardware devices: Avata Rx, a medical-grade US FDA 510(k) Class II-cleared unit covering up to 650 sq.ft. for hospitals, ICUs, IVF facilities, and pharmaceutical cleanrooms; and Avata, a consumer-grade unit covering up to 250 sq.ft. for residential use targeting newborn care, elderly care, and immunocompromised patients.

Biomoneta generates revenue through direct, quote-based hardware sales to enterprise customers in healthcare facilities, pharmaceutical/biotech cleanrooms, research institutions, and corporate environments, alongside consumer sales of the Avata residential device. The company is incorporated in India (Biomoneta Research Pvt Ltd), headquartered in Sahakara Nagar, Bangalore with an R&D laboratory at the Centre for Cellular and Molecular Platforms (C-CAMP), and operates under ISO 13485:2016, IEC 60601-1, and UL867 certifications. Its go-to-market combines product-led direct sales (enquiry-based website CTAs), scientific validation through peer-reviewed publications in Nature Scientific Reports and Journal of Hospital Infection, accelerator-driven channels (Panasonic Ignition 3.0), and earned media coverage of regulatory milestones.

Strategically, Biomoneta is at an early commercialization inflection point: it received US FDA Class II clearance for Avata Rx in December 2025, becoming the first Indian company to achieve this milestone in the air-decontamination category; secured strategic funding from the C-CAMP–Beyond Next Ventures Innovation Hub in 2024 alongside ArthaVida Ventures; and was selected as a Panasonic Ignition 3.0 ACCELERATE awardee in late 2025. The company is led by co-founders Arindam Ghatak (CEO), Janani Venkatraman (Director, ex-AstraZeneca and Bugworks founding team), and Santanu Datta (ex-AstraZeneca CSO of Bugworks), with Sujit Kumar Biswas heading engineering. The team remains small (1-10 employees), consistent with a pre-scale commercial stage despite strong regulatory and scientific positioning.

Name

Biomoneta Research

Legal name

Biomoneta Research Pvt Ltd

Website

https://biomoneta.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Short description

Biomoneta Research is a Bangalore-based health-tech company that develops ZeBox-powered air decontamination hardware for hospitals, pharmaceutical cleanrooms, research institutions, and homes, with its Avata Rx device holding US FDA Class II clearance.

Ownership category

akta.pro rank

Product category

Medical Air Decontamination Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Industrial and Commercial Fan and Blower and Air Purification Equipment Manufacturing (333413)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Disinfection & Surface Decontamination (Wipes, Sprays, Fogging, UV Robots) (HLAHANAD)

Keywords

• Air decontamination devices
• Medical air cleaners
• Infection prevention equipment
• Airborne pathogen control
• Indoor air quality systems

Headquarters

HQ city

Bangalore

HQ country

India

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Air Decontamination Device Sales: Biomoneta generates revenue through the sale of two product lines: Avata Rx (medical-grade, US FDA Class II cleared) targeting hospitals and clinical settings, and Avata (consumer-grade) for residential use including newborn care, elderly care, and immunocompromised patients. Devices are sold directly through enquiry forms and contact sales. Revenue is one-time hardware sales with potential for replacement parts and maintenance services.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Biomoneta Research designs, manufactures, and sells air decontamination hardware devices that capture and destroy airborne microorganisms in real time. Its medical-grade product, Avata Rx (US FDA 510(k) Class II cleared, covering up to 650 sq.ft.), is sold to hospitals, ICUs, operating theatres, and IVF facilities, while its consumer-grade Avata (covering up to 250 sq.ft.) is sold to residential customers for newborn, elderly, and immunocompromised use. Both products run on the proprietary ZeBox platform, which uses electric fields and microbicidal-coated electrodes to continuously eliminate >99.999% of airborne pathogens without generating ozone.

Product overview

Biomoneta Research offers a portfolio of air decontamination products powered by its proprietary ZeBox technology platform. The product line consists of Avata Rx (medical-grade, US FDA Class II cleared) for hospitals and healthcare facilities covering up to 650 sq.ft., and Avata (consumer-grade) for homes covering up to 250 sq.ft. Both products utilize the same core ZeBox technology that captures and destroys airborne microorganisms using electric fields and microbicidal agents without generating ozone or harmful radiation.

Differentiator

Problem solved

Functional benefit

Brands

• ZeBox: Proprietary air decontamination technology that electrocutes microbes upon contact, delivering medical-grade sterility without ozone or harmful radiation
• Avata Rx
• Avata

Products and services

• Avata Rx Medical-grade air decontamination device with US FDA 510(k) Class II clearance, designed for hospitals, ICUs, operating theatres, and IVF facilities. Covers up to 650 sq.ft., eliminates >99.999% of airborne microorganisms, features real-time air quality monitoring, and operates silently in occupied spaces.
• Avata Consumer-grade air decontamination device for home use, designed for newborn care, elderly care, and individuals undergoing treatment. Covers up to 250 sq.ft., with real-time air quality indicator, silent operation, and no harmful by-products (no ozone).

Quantifiable outcome

• 99.9999% (6-log) reduction in airborne SARS-CoV-2 within 5 minutes in closed environments
• +4 more outcomes

Named customers6 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core and flagship.

• Panasonic (Ignition 3.0 Accelerator)coreGTM or Marketing Partner · 1 October 2025Recognition as ACCELERATE awardee under Panasonic Ignition 3.0, an open innovation startup accelerator focused on residential living in India. The program enables pilot deployments with Panasonic and exploration of mid-term strategic partnerships for translating innovation into real-world applications. Program organized in partnership with Beyond Next Ventures.
• C-CAMP (Centre for Cellular and Molecular Platforms)flagshipStrategic or Co-development PartnerBiomoneta is a C-CAMP incubated startup. C-CAMP (Centre for Cellular and Molecular Platforms) at GKVK Campus, Bangalore provides laboratory facilities and incubation support. The partnership includes strategic funding through the CBIH innovation hub.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Novaerus (WellAir): Novaerus/WellAir manufactures plasma-based air disinfection devices for healthcare, life sciences, and commercial settings — directly comparable to Biomoneta's ZeBox in target market (hospital infection control) and product category (active air decontamination rather than HEPA filtration).
• Molekule: Molekule sells PECO (photoelectrochemical oxidation) air purifiers for consumer and commercial markets, using a proprietary active destruction technology conceptually similar to ZeBox. Competes in the premium air purifier category with consumer marketing emphasis.
• R-Zero Systems: R-Zero builds UV-based air and surface disinfection devices for healthcare, education, and commercial spaces. Direct competitor in hospital infection control with overlapping GTM motion and customer profile.
• ActivePure Technology: ActivePure manufactures active air purification technology using photocatalysis and proprietary oxidation to destroy airborne pathogens. Sold across healthcare, commercial, and consumer channels with hospital infection control as a key vertical.
• AirPHX: AirPHX produces in-duct air and surface disinfection units for healthcare and commercial HVAC systems, targeting hospital-acquired infection reduction — closely aligned with Biomoneta's pharma/biotech cleanroom and healthcare verticals.
• UV Angel: UV Angel offers UV-C air treatment systems for healthcare facilities, with a focus on continuous air disinfection in occupied spaces. Direct competitor in the hospital infection-control air treatment category.
• Plasma Air International: Plasma Air manufactures bipolar ionization air purification systems for HVAC integration across commercial, healthcare, and educational facilities. Closely comparable to Biomoneta's claim of >10X efficiency advantage versus plasma ion devices.

Broad incumbents

• Dyson Air Purifiers: Dyson is a global consumer appliance incumbent with a large air purifier product line (HEPA + activated carbon + some models with proprietary destruction technology). Competes in Biomoneta's consumer Avata segment with strong brand and retail presence.
• Philips (Philips Air): Philips is a broad incumbent in consumer air purifiers and a major supplier of medical equipment to hospitals. Competes with Biomoneta's Avata in the consumer segment and with Avata Rx via healthcare distribution relationships.
• Honeywell Air Purifiers: Honeywell is a broad incumbent with a wide range of HEPA-based air purifiers for consumer and commercial markets. Competes primarily in the residential and corporate segments where Biomoneta's Avata is positioned.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/biomoneta
• LinkedInlinkedin.com/company/biomoneta-research

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds1 record

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biomoneta Research